Serum Antibodies for Diagnosis of Inflammatory Bowel Disease
Customize your policy alerts
Sign up for all eocco policy alerts
Know when eocco releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage, and exclusions for serum antibody panels (eg, ASCA, ANCA and others), TPMT genetic/phenotypic testing, thiopurine metabolite monitoring, fecal lactoferrin, and measurement of therapeutic drug levels for diagnosis or management of inflammatory bowel disease for EOCCO members.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.